DEA Special Registration for Telemedicine: Navigating Controlled Substance Prescribing in a Post-PHE Landscape

Introduction

The landscape of telemedicine has undergone a dramatic transformation, particularly accelerated by the COVID-19 Public Health Emergency (PHE). A critical aspect of this evolution has been the ability for practitioners to prescribe controlled substances via telemedicine without an initial in-person medical evaluation, a flexibility granted under Section 309(e) of the Controlled Substances Act (CSA) waiver. With the expiration of the PHE, the Drug Enforcement Administration (DEA) has been working to establish a permanent framework for such prescribing, proposing a special registration process that aims to balance patient access with public safety concerns.

This article delves into the DEA's proposed rules for telemedicine special registration, their implications for healthcare businesses, especially multi-state telehealth platforms, and the ongoing regulatory considerations for prescribing controlled substances remotely.

Background: The Ryan Haight Act and PHE Flexibilities

Prior to the COVID-19 PHE, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally required an in-person medical evaluation before a practitioner could prescribe controlled substances to a patient. This act was designed to combat the proliferation of